Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Thoracic Malignancies
•
Medical Oncology
Do you tell your patients with epithelioid subtype mesothelioma following gross resection and adjuvant cis/pemetrexed that they have completed "curative intent" treatment?
Related Questions
How would you approach local therapy (surgery or RT) in a patient with radiographic complete response after chemoimmunotherapy for non-small-cell lung cancer?
Is there a role for nintedanib in the management of patients with radiation-induced pulmonary fibrosis?
Will you consider definitive concurrent chemoradiation for stage IV lung adenocarcinoma with metastasis limited to an internal mammary lymph node?
What is your preferred approach for managing oligoprogressive NSCLC during second-line or later systemic therapy if patient is otherwise responding well at other sites of disease?
What is your approach to radiographically suspicious lung nodules for which initial biopsy was negative for malignancy?
Would you offer consolidative durvalumab after chemoRT for an isolated mediastinal recurrence of NSCLC that occurred during adjuvant pembrolizumab given for the initial lung cancer?
What is the preferred concurrent chemotherapy regimen for limited stage small cell lung cancer with severe reaction to etoposide?
What factors do you use when selecting which NGS platform to use for sequencing solid tumors?
Would you use combination of weekly low dose carboplatin and Taxol in patient with small cell lung cancer with poor performance status or cytopenia?
Would you use Razor Genomics RiskReveal molecular testing results to guide making recommendations for surgical adjuvant chemotherapy for Stage IA,IB & II non-squamous NSCLCA ?
